Home > News > Nanogen Expands Real-Time Portfolio
April 25th, 2006
Nanogen Expands Real-Time Portfolio
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products announced today it has expanded its molecular reagent product portfolio to include real-time probes and primers designed to detect the presence of Epstein-Barr virus (EBV). EBV is the causative agent of infectious mononucleosis and also underlies several other lymphoproliferative disorders such as Burkitt's lymphoma.
Source:
Nanogen
Bookmark:
Nanomedicine
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013